A Phase 2/3 interventional study of Colchicine 0.5 MG oral tablet twice daily and Placebo Oral Tablet in Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG), sponsored by National Taiwan University Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Taiwan University Hospital · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing colchicine in Inflammation — 15 open to participants now, 18 under way, 8 of them phase 3. Colchicine · Inflammation.
Among the 35 studies testing colchicine in Inflammation, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 15 of the 17 other live ones, and was the 32nd registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →15 of the 35 studies testing colchicine in Inflammation are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
Montreal Heart Institute · Sites in Canada
Ages 40+
Mansoura University · Sites in Egypt, Saudi Arabia
Ages 18–70
Assiut University · Sites in Egypt
Ages 18+
Tan Tock Seng Hospital · Sites in Singapore
Ages 21–80
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 12 · Phase 4 4
First in 2014; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 150 across the 35 interventional studies. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 35 has an industry lead sponsor. The 10 most frequent:
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
11 studies in Inflammation by National Taiwan University Hospital: 3 open now, 3 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 11 studies in Inflammation by National Taiwan University Hospital, this one is one of 2 that started in 2026, is the only one in phase 2/3, and was the 11th registered.
National Taiwan University Hospital’s Inflammation studies by the year they started, since 2004.
7 of the studies testing colchicine in Inflammation that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05162742Phase 3Radboud University Medical CenterColchicine and Inflammation in Aortic Stenosis | 2026-12 |
| NCT07432529Phase 3Azienda Sanitaria Locale ASL 6, LivornoDesign and Rationale of the COLT Study | 2027-06-01 |
| NCT07571681Phase 3Mansoura UniversityColchicine for Autoimmune and Subacute Thyroiditis | 2027-07 |
| NCT07933757Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP | 2027-02-10 |
| NCT06217120Montreal Heart InstituteReversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 35 studies testing colchicine in Inflammation, from their registry updates:
Among National Taiwan University Hospital’s 11 in Inflammation:
This tab as a report to print or save as PDF → With an account.
Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)
This single-center, prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy of colchicine in preventing post-operative atrial fibrillation (POAF) following coronary artery bypass grafting (CABG) and to compare its pharmacologic and clinical effects between different surgical strategies - off-pump CABG (OPCAB) and on-pump CABG (ONCAB).
Post-operative atrial fibrillation is one of the most common arrhythmias after CABG, with an incidence of approximately 50%, and is associated with prolonged ICU and hospital stay and increased healthcare utilization. Intravenous amiodarone is commonly used for POAF treatment but may increase the risk of catheter-related infection. Colchicine, an anti-inflammatory and immunomodulatory agent, has shown potential to reduce postpericardiotomy syndrome and POAF in small-scale studies, but existing evidence remains inconsistent, and most prior trials did not distinguish between surgical strategies.
In this trial, 400 adult patients undergoing elective CABG will be enrolled and randomized in a 1:1 ratio within each stratum (OPCAB and ONCAB) to receive either colchicine or placebo. The treatment group will receive colchicine 0.5 mg orally twice daily, starting on postoperative day -3 and continuing through postoperative day 7. The placebo group will receive identically appearing tablets on the same schedule.
The primary endpoint is the incidence of new-onset atrial fibrillation within 14 days after surgery, defined as any episode lasting ≥30 seconds documented by 12-lead ECG, continuous telemetry, or Holter monitoring.
Secondary outcomes include the incidence and management of other arrhythmias (atrial flutter, supraventricular tachycardia), total dose and duration of intravenous amiodarone, ICU and total hospital length of stay, ischemic stroke or TIA, infection events (including catheter-related infection), and 30-day readmission. Safety outcomes will include gastrointestinal intolerance, hepatic enzyme elevation, creatine kinase elevation with myalgia, hematologic abnormalities, and serious adverse events (SAE).
Pharmacokinetic (PK) and pharmacodynamic (PD) analyses will measure colchicine concentrations in plasma and pericardial fluid and correlate these with inflammatory biomarkers (CRP, IL-6, TNF-α, white blood cell profile, and immune cell phenotyping by flow cytometry). This integrated approach aims to elucidate the relationship between colchicine exposure, inflammation, and POAF occurrence.
Statistical analyses will primarily follow an intention-to-treat (ITT) approach. The primary endpoint will be evaluated using a log-binomial or Poisson-robust model to estimate relative risk (RR) with 95% confidence intervals, including treatment, surgical strategy, and their interaction terms. Time-to-event outcomes will be analyzed using Cox proportional hazards or Kaplan-Meier methods, and continuous variables by linear mixed-effects models. Missing data will be handled conservatively with multiple imputation where appropriate. An independent Data and Safety Monitoring Board (DSMB) will review blinded safety data once 50% of subjects have been enrolled.
The trial is expected to clarify the pharmacokinetic and clinical effects of colchicine in different CABG surgical strategies. If colchicine is shown to effectively reduce POAF in OPCAB patients or in those achieving sufficient plasma concentrations, it may provide a simple, low-cost preventive strategy that reduces the need for intravenous amiodarone, lowers infection risk, and shortens ICU and hospital stay. The results could guide future optimization of dosing and timing strategies in ONCAB patients and improve perioperative management and resource utilization in cardiac surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive colchicine 0.5 mg orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).
Drug: Colchicine 0.5 MG oral tablet twice daily
Participants will receive an identically appearing placebo tablet orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).
Drug: Placebo Oral Tablet
Colchicine 0.5 mg administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7. Temporary interruption or discontinuation is permitted for clinically significant adverse events according to the study safety protocol.
Matching placebo tablet administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7 under double-blind conditions.
Percentage change in plasma colchicine concentration following initiation of cardiopulmonary bypass in the ONCAB stratum
Percentage change in plasma colchicine concentration measured 20-30 minutes after initiation of cardiopulmonary bypass (CPB) relative to the pre-anesthesia induction baseline in participants receiving colchicine in the on-pump coronary artery bypass grafting (ONCAB) stratum. Plasma colchicine concentrations will be quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This endpoint will be assessed using within-participant paired comparisons.
Time frame: From before anesthesia induction to 20-30 minutes after initiation of cardiopulmonary bypass on the day of surgery.
Incidence of new-onset atrial fibrillation or atrial flutter within 14 days after OPCAB surgery
Proportion of participants in the off-pump coronary artery bypass grafting (OPCAB) stratum who develop new-onset atrial fibrillation (AF) or atrial flutter (AFL) lasting ≥30 seconds, documented by 12-lead ECG, continuous telemetry monitoring, or 24-hour Holter recording within 14 days after surgery. The incidence will be compared between the colchicine and placebo groups. Events will be adjudicated by blinded cardiologists according to prespecified criteria.
Time frame: From the day of surgery through postoperative day 14.
Total duration of postoperative atrial fibrillation or atrial flutter
Cumulative duration (in hours) of all documented atrial fibrillation or atrial flutter episodes within 14 days after CABG surgery.
Time frame: From the day of surgery through postoperative day 14.
Proportion of participants requiring cardioversion for postoperative atrial fibrillation or atrial flutter
Percentage of participants who undergo pharmacologic or electrical cardioversion for postoperative atrial fibrillation or atrial flutter within 14 days after CABG surgery.
Time frame: From the day of surgery through postoperative day 14.
Cumulative dose of intravenous amiodarone used for POAF treatment
Total cumulative intravenous amiodarone dose (mg) administered for the treatment of postoperative atrial fibrillation or atrial flutter within 14 days after CABG surgery.
Time frame: From the day of surgery through postoperative day 14.
Length of stay in the intensive care unit (ICU)
Duration of postoperative intensive care unit (ICU) stay, measured in days, from postoperative ICU admission until ICU discharge or death, whichever occurs first.
Time frame: From postoperative ICU admission until ICU discharge or death, whichever occurs first, assessed up to 30 days after surgery.
Total hospital length of stay
Total number of days from hospital admission for CABG surgery until hospital discharge.
Time frame: From hospital admission until hospital discharge or death, whichever occurred first, assessed up to 60 days after surgery.
30-day hospital readmission
Incidence of unplanned hospital readmission for any cause within 30 days after discharge from index CABG hospitalization.
Time frame: From hospital discharge until 30 days after discharge.
Plasma and pericardial fluid colchicine concentrations
Measured colchicine concentrations (ng/mL) in plasma and pericardial fluid at predefined perioperative time points(preoperative baseline, end of surgery, postoperative day 1, postoperative day 3, and postoperative day 7)for pharmacokinetic analysis.
Time frame: From preoperative day 1 through postoperative day 7.
Plan to share: No — The individual participant data (IPD) collected in this study will not be shared because they include sensitive clinical and biological information linked to hospital medical records. Data sharing is restricted by institutional and national privacy regulations. Only de-identified, aggregate summary data will be available in publications or presentations after study completion.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 30 phase 2/3 interventional studies under Inflammation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 29 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2028 → Dec 2028 and completion Jul 2028 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
National Taiwan University Hospital →